Show simple item record

dc.contributor.authorVela Soria, Fernando 
dc.contributor.authorMustieles Miralles, Vicente 
dc.contributor.authorFernández Cabrera, Mariana Fátima 
dc.date.accessioned2020-11-16T08:13:25Z
dc.date.available2020-11-16T08:13:25Z
dc.date.issued2020
dc.identifier.citationVela-Soria, F., García-Villanova, J., Mustieles, V., de Haro, T., Antignac, J. P., & Fernandez, M. F. (2020). Assessment of perfluoroalkyl substances in placenta by coupling salt assisted liquid-liquid extraction with dispersive liquid-liquid microextraction prior to liquid chromatography-tandem mass spectrometry. Talanta, 221, 121577. [DOI: 10.1016/j.talanta.2020.121577]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/64279
dc.description.abstractThe widespread use of perfluoroalkyl substances (PFAS) is resulting in a broad human exposure to these endocrine disrupting chemicals (EDCs), prompting biomonitoring research to evaluate its magnitude and impact, especially during critical windows of exposure such as fetal and perinatal periods. This study was focused on developing a method to determine 10 PFAS in placental tissue by combining salt-assisted liquid-liquid extraction with dispersive liquid-liquid microextraction and using liquid chromatography-tandem mass spectrometry. Chemometric strategies were applied to optimize the experimental parameters. The limit of quantification was 0.02 ng g− 1 for all analytes, and the inter-day variability (as relative standard deviation) ranged from 7.9% to 13.8%. Recoveries ranged from 88.2% to 113.9%. The suitableness of the procedure was demonstrated by assessing the targeted compounds in 20 placenta samples. The highest concentrations were recorded for perfluorooctanoic acid and perfluorooctane sulfonate, with maximum concentrations of 0.62 and 1.02 ng g− 1 and median concentrations of 0.13 and 0.53 ng g− 1 , respectively. Median concentrations of the other PFAS ranged from detected values to 0.08 ng g− 1 . This analytical procedure yields useful data on fetal exposure to PFAS.es_ES
dc.description.sponsorshipEuropean Union's Horizon 2020 research and innovation programme 733032es_ES
dc.description.sponsorshipInstituto de Salud Carlos III FIS-PI16/01820 FIS-PI16/01812 FIS-PI16/01858es_ES
dc.description.sponsorshipInstituto de Salud Carlos IIIes_ES
dc.description.sponsorship"Fondo Europeo de Desarrollo Regional" (ISCIII/FEDER) CD17/00212es_ES
dc.language.isoenges_ES
dc.publisherELSEVIERes_ES
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectPerfluoroalkyl substanceses_ES
dc.subjectPlacenta es_ES
dc.subjectDispersive liquid-liquid microextractiones_ES
dc.subjectLC–MS/MSes_ES
dc.subjectHBM4EUes_ES
dc.titleAssessment of perfluoroalkyl substances in placenta by coupling salt assisted liquid-liquid extraction with dispersive liquid-liquid microextraction prior to liquid chromatography-tandem mass spectrometryes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.projectIDeu-repo/grantAgreement/EC/H2020/733032es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1016/j.talanta.2020.121577


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España